Passage Bio

149 articles about Passage Bio

• Passage Bio Announces Leadership Transition

  6/1/2022

  Bruce Goldsmith, Ph.D. to step down as president and chief executive officer and member of board of directors, will serve as a strategic advisor for a transition period Edgar B. (Chip) Cale, current general counsel and corporate secretary, appointed as interim chief executive officer.

• Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - May 20, 2022

  5/20/2022

  Passage Bio, Inc., a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, announced it has granted inducement awards to new employees.

• Passage Bio Presents New Interim Clinical and Biomarker Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at ASGCT 25th Annual Meeting

  5/18/2022

  Passage Bio Presents New Interim Clinical and Biomarker Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at ASGCT 25th Annual Meeting.

• Passage Bio Reports First Quarter 2022 Financial Results and Provides Recent Business Highlights

  5/16/2022

  Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today reported financial results for the first quarter ended March 31, 2022 and provided recent business highlights.

• Passage Bio to Report First Quarter 2022 Financial Results on May 16, 2022

  5/9/2022

  Passage Bio, Inc. announced that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, May 16, 2022, to report its first quarter 2022 financial results and discuss recent business highlights.

• UPDATE - Passage Bio to Present Updated Imagine-1 Study Clinical and Biomarker Data at the American Society of Gene and Cell Therapy 25th Annual Meeting

  5/3/2022

  Passage Bio, Inc. announced that additional clinical and biomarker data from Cohort 1 in the Imagine-1 study for GM1 gangliosidosis will be presented at the upcoming American Society of Gene and Cell Therapy 25th Annual Meeting, which is being held in Washington, D.C. and virtually on May 16-19, 2022.

• Passage Bio to Present Updated Imagine-1 Study Clinical and Biomarker Data at the American Society of Gene and Cell Therapy 25th Annual Meeting

  5/2/2022

  Passage Bio, Inc. announced that additional clinical and biomarker data from Cohort 1 in the Imagine-1 study for GM1 gangliosidosis will be presented at the upcoming American Society of Gene and Cell Therapy 25th Annual Meeting, which is being held in Washington D.C. and virtually from May 16 to 19, 2022.

• Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Apr 22, 2022

  4/22/2022

  Passage Bio, Inc., a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, announced it has granted inducement awards to new employees.

• Passage Bio Announces Publication of Preclinical Data that Support Ongoing Clinical Study of PBKR03 in Krabbe Disease

  3/29/2022

  Preclinical studies conducted with University of Pennsylvania’s Gene Therapy Program demonstrate biologic effects of vector-optimized gene therapy PBKR03 for Krabbe disease PBKR03 showed marked improvements in safety, disease progression and key biomarkers for Krabbe disease in large and small animal models Company is enrolling patients for cohort 1 in global clinical trial, GALax-C, with PBKR03 for infantile Krabbe disease, a rare, fatal pediatric condition PHILADELPHIA, March 29, 2022 (G

• Passage Bio to Participate in Upcoming Investor Conferences - Mar 28, 2022

  3/28/2022

  Passage Bio, Inc., a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, announced that management will participate in the following upcoming virtual investor conferences.

• Passage Bio Provides Update on Strategic Priorities and Extends Cash Runway

  3/15/2022

  Passage Bio, Inc., a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, provided an update on strategic priorities to extend its cash runway.

• 

  Passage Bio Culls 13% of Headcount, Prioritizes Gene Therapy 

  3/15/2022

  Less than one week after dosing the first patient in a Phase I/II gene therapy trial for early infantile Krabbe disease, Passage Bio announced it was cutting its headcount by 13% in order to preserve cash runway.

• Passage Bio Doses First Patient in Global Clinical Trial for Infantile Krabbe Disease, A Rare Fatal Pediatric Condition

  3/10/2022

  Passage Bio, Inc., a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, announced that the first patient with early infantile Krabbe disease has received PBKR03, an adeno-associated virus -delivery gene therapy, in its global Phase 1/2 clinical trial, GALax-C.

• Passage Bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights

  3/3/2022

  Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided recent business highlights.

• Passage Bio to Participate in Upcoming March 2022 Investor Conferences

  3/1/2022

  Passage Bio, Inc., a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, announced that management will participate in two upcoming virtual investor conferences in March.

• Passage Bio to Report Fourth Quarter and Full-Year 2021 Financial Results on March 3, 2022

  2/24/2022

  Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 3, 2022 to report its fourth quarter and full-year 2021 financial results and discuss recent business highlights.

• Passage Bio Presents New Interim Clinical Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at 2022 WORLDSymposium

  2/11/2022

  Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today presented updated clinical data from Imagine-1, a Phase 1/2 study of PBGM01, a gene therapy for GM1 gangliosidosis (GM1).

• Passage Bio to Showcase GM1 Gangliosidosis and Krabbe Clinical Programs at 2022 WORLDSymposium, February 7 – 11

  1/31/2022

  Passage Bio, Inc. announced its participation at the 18th Annual WORLDSymposium, a research conference dedicated to lysosomal diseases, taking place virtually and in person in San Diego, Calif., February 7 – 11, 2022.

• Passage Bio Announces 2022 Research and Clinical Development Goals to Advance Robust CNS Pipeline

  1/10/2022

  Passage Bio, Inc., a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, will share the company’s 2022 outlook in a presentation at the 40th Annual J.P. Morgan Healthcare Conference.

• Passage Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference

  1/3/2022

  Passage Bio, Inc. today announced that Bruce Goldsmith, Ph.D., president, and chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference being held virtually on Monday, January 10, 2022 at 10:30 a.m. ET.